Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04513366 · ClinicalTrials.gov registry record · Phase 3
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
A Phase 3 study of Chronic Gout, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT04513366: Completed Phase 3 study of Chronic Gout, sponsored by Swedish Orphan Biovitrum.
NCT04513366 is a Phase 3 study of Chronic Gout that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 112 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04513366, a Phase 3 study of Chronic Gout, has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy was performed at Day 28 of Treatment Period 6. Safety was monitored throughout the study.
Conditions Studied
Interventions
- OTHER Normal Saline
- DRUG SEL-212 low-dose
- DRUG SEL-212 high-dose
Study Locations (20)
Florida
- Helix Biomedics, LLC - Boynton Beach
- Clinical Research Of West Florida Incorporated - Clearwater
- Omegas Research Consultants LLC - DeBary
- Riverside Clinical Research - Edgewater
- Homestead Associates in Research,Inc - Homestead
- Health Awareness INC - Jupiter
- Y & L Advance Health Care, Inc - Miami
- Well Pharma Medical Research, Corp - Miami
- Panax Clinical Research - Miami Lakes
- Clinical Research of West Florida, Inc. - Tampa
- Conquest Research - Winter Park
California
- Medvin Clinical Research - Covina
- Valerius Medical Group & Research Center - Los Alamitos
- ACRC Studies - Poway
- MD Strategies Research Center - San Diego
Alabama
- Pinnacle Research Group - Anniston
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC - Sun City
Colorado
- Tekton Research - Fort Collins - Fort Collins
Georgia
- Better Health Clinical Research, Inc. - Newnan
Idaho
- Institute of Arthritis Research - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 3 |
What the finished NCT04513366 record still lists
NCT04513366 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Chronic Gout appearing as the primary indexed condition, and to 3 interventions - of which Normal Saline is the first listed.
NCT04513366 names 20 study sites across 7 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04513366 about?
NCT04513366 is a clinical study titled "A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy". This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocat...
What is the current status of trial NCT04513366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2020-08-18. Estimated completion is 2022-12-01.
What conditions does trial NCT04513366 study?
This clinical trial studies the following conditions: Chronic Gout.
What interventions are being tested in trial NCT04513366?
The interventions under investigation include: Normal Saline (OTHER), SEL-212 low-dose (DRUG), SEL-212 high-dose (DRUG).
Who is sponsoring clinical trial NCT04513366?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04513366 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04513366's enrollment target sits among peer trials
112 1652nd of 2000 higher than 346 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI